What is ADXN stock price today?

ADXN (Addex Therapeutics Ltd) stock is trading at $7.17 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ADXN stock going up or down today?

ADXN stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ADXN stock now?

The decision to buy ADXN depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ADXN a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ADXN based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ADXN stock overvalued or undervalued?

Use our DCF valuation calculator to determine if ADXN is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is ADXN's P/E ratio?

P/E ratio data for ADXN will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is ADXN's market cap?

ADXN (Addex Therapeutics Ltd) has a market capitalization of $0.01 billion, making it a small-cap stock.

What is ADXN's price to book ratio?

ADXN trades at a price-to-book (P/B) ratio of 1.14, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does ADXN pay dividends?

ADXN does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ADXN's dividend yield?

ADXN does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ADXN stock a good long-term investment?

ADXN's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ADXN's revenue growth rate?

ADXN has shown revenue growth of -0.1% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for ADXN are available on our dashboard with complete income statement analysis.

What are the risks of investing in ADXN?

Key risks for ADXN include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ADXN compare to its competitors?

Compare ADXN to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ADXN's performance and positioning.

What is ADXN's stock price target for 2026?

Our AI model provides price targets for ADXN based on fundamental analysis: Bull case $9.32 (+30%), Base case $8.25 (+15%), Bear case $6.45 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ADXN?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ADXN. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ADXN's next earnings report?

ADXN reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ADXN - Addex Therapeutics Ltd

NYSE * Health Care * Biotechnology

$7.17

+$0.12 (+1.70%)

About Addex Therapeutics Ltd

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

ADXN Key Statistics

Market Cap

$8.83M

P/B Ratio

1.14

EPS

$-9.40

Revenue Growth

-0.1%

Employees

How ADXN Compares to Peers

ADXN is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
ADXN(This stock)	$8.83M	N/A	-0%	0.0%	-
AMGNAmgen Inc	$199.20B	25.8	0%	0.2%	vs AMGN
GILDGilead Sciences	$178.68B	21.4	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$116.00B	30.1	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$80.33B	18.5	0%	0.3%	vs REGN
BIIBBiogen Inc	$27.13B	21.4	-0%	0.1%	vs BIIB

Addex Therapeutics Ltd Company Information

Headquarters: Switzerland
Website: www.addextherapeutics.com
Sector: Health Care
Industry: Biotechnology

About Addex Therapeutics Ltd

ADXN Key Statistics

How ADXN Compares to Peers

Addex Therapeutics Ltd Company Information

Upcoming Events for ADXN